Related Experiment Video

Updated: May 15, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug

Muhammad Khattak1, James Larkin

  • 1Department of Medical Oncology, Royal Marsden NHS Trust, Fulham Road, London, SW3 6JJ, UK.

World Journal of Urology
|January 9, 2013
PubMed

Insights

Most advanced renal cell carcinoma patients develop resistance to targeted therapies. Further anti-angiogenic therapy may benefit patients after progressing on two targeted agents, but more randomized data are needed.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Renal cell carcinoma (RCC) is a growing malignancy, with increasing incidence.
  • Advances in targeted agents have improved survival for advanced RCC, but drug resistance remains a significant challenge.
  • Understanding resistance mechanisms is crucial for developing effective treatment strategies.

Purpose of the Study:

  • To evaluate the potential benefit of further anti-angiogenic therapy in advanced renal cell carcinoma (RCC) patients who have progressed on prior targeted agents.
  • To explore strategies for overcoming or delaying resistance to targeted therapies in advanced RCC.
  • To identify the role of anti-angiogenic agents beyond second-line therapy in RCC treatment.

Main Methods:

  • Review of retrospective data on sequential and combination therapies in advanced renal cell carcinoma.
  • Evaluation of anti-angiogenic therapy following progression on two targeted agents with similar or different mechanisms of action.
  • Analysis of clinical benefit and drug resistance patterns in advanced RCC patients.

Main Results:

  • Retrospective data suggest potential benefit from further anti-angiogenic therapy in advanced RCC after progression on two targeted agents.
  • Sequential and combination therapies are being explored to maintain clinical benefit and overcome resistance.
  • Current data highlight the need for more robust evidence regarding treatment beyond second-line therapy.

Conclusions:

  • Further anti-angiogenic therapy may be a viable option for advanced renal cell carcinoma patients progressing on prior targeted treatments.
  • Overcoming targeted agent resistance in advanced RCC requires continued investigation into novel therapeutic strategies.
  • Randomized clinical trials are essential to confirm the efficacy and define the optimal role of anti-angiogenic agents in later lines of RCC therapy.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...